HARBOUR INVESTMENTS, INC. - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 49 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q2 2022. The put-call ratio across all filers is 0.17 and the average weighting 0.0%.

Quarter-by-quarter ownership
HARBOUR INVESTMENTS, INC. ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q3 2023$159
-94.8%
796
-46.0%
0.00%
Q2 2023$3,039
-37.6%
1,4750.0%0.00%
Q1 2023$4,868
+66.7%
1,475
-17.2%
0.00%
Q4 2022$2,921
-58.3%
1,781
-32.4%
0.00%
Q3 2022$7,0000.0%2,6340.0%0.00%
Q2 2022$7,000
-61.1%
2,634
-40.1%
0.00%
-100.0%
Q4 2021$18,000
-33.3%
4,399
-46.8%
0.00%0.0%
Q3 2021$27,000
-25.0%
8,269
-12.4%
0.00%0.0%
Q2 2021$36,0000.0%9,444
-0.1%
0.00%0.0%
Q1 2021$36,0009,4550.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q2 2022
NameSharesValueWeighting ↓
ABNER HERRMAN & BROCK LLC 239,000$2,679,0000.48%
EAM Investors, LLC 81,854$918,0000.20%
CFO4Life Group, LLC 12,003$135,0000.05%
Phoenix Holdings Ltd. 104,782$1,112,0000.05%
WINTON GROUP Ltd 118,487$1,328,0000.03%
Merit Financial Group, LLC 28,731$322,0000.03%
HighPoint Advisor Group LLC 13,533$151,0000.03%
SHANDA ASSET MANAGEMENT HOLDINGS Ltd 23,000$258,0000.02%
ETF MANAGERS GROUP, LLC 52,216$579,0000.02%
IHT Wealth Management, LLC 13,000$146,0000.02%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders